Zobrazeno 1 - 10
of 1 467
pro vyhledávání: '"G. Németh"'
Publikováno v:
European Psychiatry, Vol 67, Pp S211-S211 (2024)
Introduction Schizophrenia is a chronic neuropsychiatric disorder that often requires long-term pharmacotherapy to manage symptoms and prevent relapse. There are important clinical differences between early-stage versus late-stage schizophrenia, like
Externí odkaz:
https://doaj.org/article/988fdc3af4764ae78750554fc060fe2b
Publikováno v:
European Psychiatry, Vol 67, Pp S215-S215 (2024)
Introduction The treatment of dual disorders, the co-occurrence of a major psychiatric disorder and a substance use disorder, represents a great challenge. Recent articles recommend antipsychotics with a dopamine partial agonism as first line treatme
Externí odkaz:
https://doaj.org/article/aea4f393ac77465dab473a655ac49235
Publikováno v:
European Psychiatry, Vol 66, Pp S641-S641 (2023)
Introduction There is an increasing need to understand the effectiveness of novel medications in real-world context since despite being the gold standard, double-blind trials have their own limitations as well. Clinical Global Impression is a simple
Externí odkaz:
https://doaj.org/article/5279e123654247068088c55b14128fd2
Publikováno v:
European Psychiatry, Vol 66, Pp S297-S298 (2023)
Introduction Depressive symptoms are a common feature of schizophrenia (SCH) and define bipolar disorder and major depressive disorder (MDD). Their emergence is related to altered neurotransmission at the serotonin receptors and potentially at dopami
Externí odkaz:
https://doaj.org/article/58379a0dad1d40678ff3718043a2075f
Autor:
G. Németh
Publikováno v:
European Psychiatry, Vol 65, Pp S33-S33 (2022)
Although antipsychotics were discovered over fifty years ago, it took another decade until dopamine antagonism was demonstrated as central to their clinical effectiveness. Since accumulated evidence implicates the dopamine system in the pathophysiolo
Externí odkaz:
https://doaj.org/article/5c6e3d8e5dc74c1fa33d5bc9b3819876
Publikováno v:
European Psychiatry, Vol 65, Pp S156-S157 (2022)
Introduction Affective symptoms are a common feature of schizophrenia and define bipolar disorder. Alterations in dopamine neurotransmission and activity at D3-D2 receptors is associated with depressive symptoms providing the rationale for targeting
Externí odkaz:
https://doaj.org/article/65c2fc7d2ef546e1b5575ef7fd983c13
Publikováno v:
European Psychiatry, Vol 65, Pp S323-S323 (2022)
Introduction Chronic schizophrenia patients are experiencing persistent and severe illness for more than 15-20 years and are usually suffering from long-term negative symptoms. Cariprazine, a novel D3-D2 partial agonist has been proven to be effectiv
Externí odkaz:
https://doaj.org/article/e8d56f318653491f8ff73de56281d02d
Publikováno v:
European Psychiatry, Vol 64, Pp S533-S533 (2021)
Introduction Motivation deficit is a significant aspect of lack of improvement in patients with schizophrenia especially with predominant negative symptoms (PNS). Therefore, improvement depends not only on symptoms reduction and better social functio
Externí odkaz:
https://doaj.org/article/97ccc4ae2ba14766a060cd22b05c1cda
Publikováno v:
European Psychiatry, Vol 64, Pp S533-S534 (2021)
Introduction Although monotherapy is preferable, in every day clinical practice polypharmacy is often unavoidable due to the need of treatment enhancement or cross-titration phases with shorter or longer overlaps of two or more drugs. However, admini
Externí odkaz:
https://doaj.org/article/9813f3b429e14917b7797ae77a3ab5ca
Autor:
Z.B. Dombi, K. Acsai, Á. Barabássy, B. Sebe, I. Laszlovszky, G. Vass, B. Szatmári, M. Patel, W. Earley, G. Németh
Publikováno v:
European Psychiatry, Vol 64, Pp S524-S525 (2021)
Introduction In the early stage of schizophrenia (first 5 years), the most important clinical target besides symptom control is relapse prevention as each relapse significantly decreases the possibility of preferable long-term outcomes. Early discont
Externí odkaz:
https://doaj.org/article/43893400657545a09842ce8621402f65